This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Humana (HUM) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $347.19, signifying a -0.28% move from its prior day's close.
CI or HUM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Are These 3 Beaten-Down S&P 500 Members Worth a Look?
by Derek Lewis
The market has enjoyed a fantastic run in 2024, building nicely on last year???s gains. But not all have joined the party, specifically these three. Deep in the red year-to-date, are they worth a look?
Humana (HUM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $345.15, moving -0.53% from the previous trading session.
Humana (HUM) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Humana (HUM) closed at $339.08, marking a +0.34% move from the previous day.
Humana (HUM) Inks Value-Based Deal to Offer Better Kidney Care
by Zacks Equity Research
Humana (HUM) expands ties with Strive to offer high-quality kidney care to its Medicare Advantage members and thereby, aims to increase the customer base of the relevant business line.
Cardinal Health and Humana have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cardinal Health and Humana have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Humana (HUM)
by Derek Lewis
Increased costs have been a thorn in the side of Humana, with shares facing a nasty reaction post-earnings following its latest quarterly release.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
Humana (HUM) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, Humana (HUM) stood at $350.32, denoting a -0.24% change from the preceding trading day.
Humana (HUM) Collaborates With Veda to Enhance Efficiency
by Zacks Equity Research
Humana (HUM) partners with Veda to enhance the quality of provider directories.
Is It Worth Investing in Humana (HUM) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Humana (HUM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
CNC or HUM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CNC vs. HUM: Which Stock Is the Better Value Option?
CNC vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNC vs. HUM: Which Stock Is the Better Value Option?
Humana (HUM) Q4 Earnings Miss on Higher Costs, '25 Target Pulled
by Zacks Equity Research
Humana (HUM) expects 2024 revenues to increase to around $113 billion.
Compared to Estimates, Humana (HUM) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Humana (HUM) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of -57.14% and 1.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ahead of Humana (HUM) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Humana (HUM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Forget About a March Rate Cut: Focus on These 3 Stocks Poised to Rally
by Ethan Feller
Strong jobs data this morning shows just how strong the labor market is limiting the odds of rate cuts
Here's Why Humana (HUM) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Humana (HUM) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $459.30 in the latest trading session, marking a -0.31% move from the prior day.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?
by Zacks Equity Research
Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.